CAS 113104-25-9

NSC228155

Description:

NSC228155, also known by its CAS number 113104-25-9, is a chemical compound that has garnered interest in the field of medicinal chemistry, particularly for its potential applications in cancer treatment. It is characterized as a small molecule with a specific structure that allows it to interact with biological targets, potentially inhibiting tumor growth or altering cellular processes. The compound's mechanism of action may involve interference with specific signaling pathways or cellular functions, making it a candidate for further research in oncology. Additionally, NSC228155 may exhibit properties such as solubility in various solvents, stability under certain conditions, and specific reactivity with biological macromolecules. Its pharmacokinetic and pharmacodynamic profiles are crucial for understanding its efficacy and safety in therapeutic contexts. As with many investigational compounds, ongoing studies are necessary to fully elucidate its characteristics, including its toxicity, bioavailability, and overall therapeutic potential.

Formula: C₁₁H₆N₄O₄S

Synonyms:

• NSC228155
• NSC-228155;NSC 228155
• NSC228155;NSC-228155;NSC 228155
• 2-[(7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)thio]pyridine 1-oxide

NSC228155

CAS: 113104-25-9

Formula: C₁₁H₆N₄O₄S

Purity: 99%

Color and Shape: Solid

Molecular weight: 290.2547

Ref: IN-DA01EQHV

NSC 228155

CAS: 113104-25-9

NSC 228155

Purity: ≥95%

Molecular weight: 290.25g/mol

Ref: 54-BUP10568

NSC 228155

CAS: 113104-25-9

NSC 228155 is an activator of EGFR, binding to the sEGFR dimerization domain II and modulate EGFR tyrosine phosphorylation.

Formula: C₁₁H₆N₄O₄S

Purity: 99.84%

Color and Shape: Solid

Molecular weight: 290.25

Ref: TM-T6908

NSC 228155

CAS: 113104-25-9

NSC 228155 is a potent and selective inhibitor of histone deacetylases (HDACs) with anti-cancer activity. It was shown to inhibit the growth of human breast cancer cells, mda-mb-231, in culture by blocking the production of epidermal growth factor (EGF). NSC 228155 has a low toxicity profile and is effective at low doses. It inhibits angiogenesis through its ability to inhibit endothelial cell proliferation and migration. NSC 228155 also inhibits the growth of other types of cancer cells such as prostate cancer cells, colon cancer cells, and leukemia cells. The inhibition of HDACs leads to an increase in histone H3 acetylation levels and an increase in transcriptional activation. This results in higher protein synthesis rates and cell proliferation.

Formula: C₁₁H₆N₄O₄S

Purity: Min. 95%

Molecular weight: 290.25 g/mol

Ref: 3D-NEA10425